August 18, 2021
Longeveron has just announced the first data from its Phase 2b clinical trial that targets frailty with Lomecel-B, an MSC-based cell therapy. A longevity strategy built in More and more, biotech start-ups are applying longevity strategies to their therapeutic pipelines. Among them, Longeveron stands out as one of the few companies taking a cell-based approach....